Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03161366|
Recruitment Status : Completed
First Posted : May 19, 2017
Last Update Posted : December 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|Ebola Virus Disease||Biological: rVSVΔG-ZEBOV-GP||Phase 3|
Ebola Virus Disease remains ill-known by populations, creating fear and mistrust, is highly contagious, requiring strict isolation measures and with only supportive therapy available that has limited impact on case-fatality which remains high (30 -80%).1 Among vaccines in development, the rVSVΔG-ZEBOV-GP vaccine has given the most promising results in terms of efficacy and safety having been evaluated now in more than 10,000 individuals.
Ring vaccination is a known strategy to control epidemics with specific transmission chains and has been successfully implemented to eradicate smallpox. Ring vaccination enhances standard public health measures of contact tracing, isolation, and community engagement and could be effective when such measures are in place. Building on the interim results of the Ebola ça Suffit trial, there is a need for continued access to a vaccine of which available results suggest that it is safe and likely efficacious against EVD. Although only isolated cases have been reported in Guinea, Sierra Leone and Liberia in 2016, 10 the risk of resurgence or of continued isolated cases in West Africa remains. Moreover, a new outbreak with Ebola Zaïre could start any moment in any of the countries where previous outbreaks occurred as in for example Democratic Republic of Congo and Uganda.
However, the unusual design of the ring trial and the decision to abandon the control group because of strong evidence that the vaccine prevented disease means there may not be enough data to ensure approval from regulatory agencies. Therefore, additional information is still required to consolidate knowledge on the rVSVΔG-ZEBOV-GP vaccine to support regulatory approval and licensure for future access. Additional information is also needed on ring vaccination and contextual adaptations to this approach to ensure its feasibility and effectiveness in the control of Ebola outbreaks in potentially diverse contexts.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||500 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Interventional, single arm, open-label, non-randomized|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP|
|Actual Study Start Date :||May 28, 2018|
|Actual Primary Completion Date :||July 14, 2018|
|Actual Study Completion Date :||November 30, 2018|
Experimental: Single arm
Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
- Cumulative incidence [ Time Frame: 84 days after vaccination ]Occurrence of Ebola Zaire cases amongst contacts and contacts of contacts
- Assessment of Adverse and Serious Adverse Events [ Time Frame: 84 days after vaccination ]Safety of a single dose of rVSVΔG-ZEBOV-GP
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161366
|Congo, The Democratic Republic of the|
|Médecins Sans Frontières|
|Kinshasa, Congo, The Democratic Republic of the|
|Mbarara, Uganda, 1956|